The decentralization of analysis at the emergency room is a well-established practice, in particular for the use of blood gas analysis. Recently, many other analyzers have been proposed, with rapid methods that can potentially reduce the response time of the tests. Here we consider the various analyzers that can be used at the bedside, their advantages and limits, the related scientific evidences. Finally, we discuss their impact both on patient care and on accelerating the patient's flow in the emergency room.
Introduction
Quick availability of laboratory tests is a critical issue for the Emergency Department (ED). Continuous request for a shorter turnaround time (TAT) is frequently experienced by almost all laboratories that perform urgent exams. Two are the reasons for this need: first, the possibility of an early intervention in critically ill patients. Second, the purpose of facilitating the taking charge, even in non-critical subjects. Therefore the adoption of the point-of-care testing (POCT) can also contribute to containment of the crowding of waiting rooms. In the case of the most serious patients the choice of a blood gas analyzer placed in the examination room in the main hospitals has made a major contribution to the treatment of dyspnea, metabolic disorders, sepsis, and renal failure. So, the POCT in emergency is an experience consolidated for many years. Over the last decades a lot of new, easy to use, speedy devices for several analytes have been proposed on the market. There are numerous methods available from different suppliers for various laboratory analyses: blood gas, electrolytes, basic biochemistry, hematology, coagulation, inflammation markers, cardiac markers, toxicology, urinalysis, pregnancy, infections and serology (Table  1) . Development in this field is constantly expanding and the global point-of-care diagnostics market is projected to reach 38.13 billion USD by 2022 from 23.71 billion USD in 2017. 1 To test at the bedside is not a new as laboratory medicine was born precisely in this way, with the examination of urine and other biological fluids directly near the patient; then in the '30s testing was moved to suitable premises with dedicated instruments. Later the laboratories grew and became a discipline with a complex structure but the reverse process of returning to the clinical department is a more recent event that requires standardized procedures and quality assurance.
It is usually performed by staff without laboratory training, although also encompasses patient self-monitoring. POCT provides rapid results near the patient which can be acted upon immediately. By contrast, analysis in the clinical laboratory could at times incur significant delays in TAT.
The estimation of TAT is often referred to the intra-laboratory phases which are more easily extracted from the informatics databases of the laboratories. It would instead be desirable to always refer to the diagnostic cycle described by Lundberg that includes the complete pathway from the clinical question up until the clinical action, both diagnostic or therapeutic 2 ( Figure 1 ). If we consider this overall time the clinical laboratories can keep the TAT under 60 minutes with difficulty. In fact, the time required for blood collection, identification of the tubes, transport to the laboratory through the pneumatic tube system takes about 5-10 minutes. In the laboratory the phases depend on the workload and the specific tests required: an average values of at least 35 minutes are usual. From this description it is clear how the 90th percentile easily settles on 70-100 minutes. It is therefore understandable that the POCT test has in any case an advantage of unquestionable speed, at least as long as one test is requested at a time.
Is the use of point-of-care testing analyzers in emergency department supported by efficacy evidences?
The clinical scenarios where the POCT were investigated by evidence-based studies is limited to some specific cases such as: remote rural communities, primary care medicine, self-monitoring, pharmacies, drugs of abuse and finally the ED. 3 In this field some papers explored the specific diagnostic conditions related to dyspnea (Brain Natriuretic Peptide), thromboembolism (D-dimer), sepsis (lactate), metabolism (blood gas and electrolytes), pregnancy (human Chorionic Gonadotropin) and acute coronary syndrome with the use of troponins. Most of the studies do not reach high qual- ity levels and express opinions of experts based on limited series. 3 A study using a randomized and prospective methodology in 1728 subjects, verified the impact of a basic biochemical profile in a British emergency room; a half of patients were randomly managed with a rapid test, while others performed the tests at a centralized laboratory. 4 Unfortunately, a study with these characteristics has not been conducted since 1998, but we can still consider it valid in the main conclusions: TAT has been shown to be reduced; in about 7% of patients appropriate therapy was started earlier, but the length of stay (LOS) in ED has not improved and overall mortality has not decreased. Therefore, some organizational advantage was demonstrated with no improvement of clinical outcome.
A more recent experience was evidenced by Levandrowski at the Massachusetts General Hospital: typical POCT instruments were used near an ED, but managed directly by laboratory staff (glucose, coagulation, urine pregnancy, dipstick urinalysis, creatine kinase-MB and Cardiac Troponin (cTn). 5 Some of the tests decreased ED LOS (urine testing, rapid D-dimer), whereas other test results allowed rapid diagnosis and triage of patients presenting to the ED. We can conclude that rapid analytical methodologies can offer some clinical advantages, even if the evidence is not fully demonstrated. Figure 2 shows that the reduction in laboratory TAT contributes only partially to a potential reduction of ED LOS because the variables that determine it are several others.
Laboratory exams in disadvantaged areas
The use of POCT is particularly suitable where the first aid takes place in remote, rural areas, smaller islands, aircraft, ships, environments with low atmospheric pressure or gravitation, in countries without a land rescue system. In all these conditions, efficacy studies and evaluations were carried out using portable analytical systems. An experience in New Zealand, for example, has shown in particular an advantage of POCT in the treatment of less severe patients, where an immediate test made it possible to reduce transfers to the base hospital by 62% with an increase in discharges. 6 Other positive clinical results have been reported with moderate levels of evidence in the management of acute coronary syndromes (ACS) in rural areas in Australia through the use of troponin determination in the field. 7
Point-of-care testing troponins and acute coronary syndrome
Chest pain is one of the most relevant presenting symptoms in ED and the consequent determination of cTn is essential to the ACS classification when the ECG pattern is not clear. Clinical laboratories have continuously improved the performance of this test, in particular the analytical sensitivity and consequently its diagnostic precocity. High-sensitivity cTn assays (hs-cTn), as defined today, should have coefficient of variation ≤10% at the 99th percentile of cTn concentrations seen in healthy individuals. In addition, the measured concentration should exceed the limit of detection in at least 50% (ideally 95%) of healthy subjects. 8 9 Only recently there is a POCT test on the market that the manufacturer affirms in accordance to the definition of high sensitivity, the first cTn high sensitivity cleared by the Food and Drug Administration, as confirmed in a preliminary study. 10 Other methods are under development, but right now the choice of an instrument that complies with the recommendations is very limited at this time. 9 Most published studies have compared the POCT cTn with conventional cTn assays performed at the laboratory. Little data are available on the comparison of POCT cTn with a conventional hs-cTn. Some manufacturers of cardiac POCT instruments propose the association of other markers in various combinations, such as Creatine Kinase MB, Myoglobin, Brain Natriuretic Peptide, D-dimer, C-reactive protein. Some of these are no longer recommended by cardiology guidelines and can often be considered as completely inappropriate. Only the combination of a hscTn with Copeptin seems to have a greater diagnostic accuracy, but this does not happen with cTn of lower analytical quality. 
Point-of-care testing in other clinical conditions
The combination of D-dimer test with clinical assessment is effective to exclude venous thrombo-embolism in low pre-test probability patients. This statement is particularly valid if the test has negative predictive value of more than 98% and a TAT of less than 38 minutes. 12 Some assays dedicated to the POCT have these characteristics, although some papers have discussed the value of tests with analytical performance lower than those of the laboratory. Unfortunately, the conditions present in an ED often prompt doctors to request this test inappropriately. 13 In the case of suspected sepsis, a rapid TAT for both tests and treatments is recommended by the Surviving Sepsis Campaign guidelines specifically indicating a limited number of laboratory tests such as Blood gas, Platelet count, Creatinine, Bilirubin and Lactic acid.
14 These tests are related to the initial diagnosis of sepsis or septic shock by the Sequential Organ Failure Assessment score. There is no published evidence on the use of POCT for this specific diagnosis that cannot be resolved by using a single instrument. Moreover, we have to consider that several other laboratory markers are suitable to identify the type of patients who are often complicated by concurrent diseases: Leukocytes count, immature Granulocytes, coagulation tests, C-reactive protein, Procalcitonin, Presepsin, Urinalysis, microbiological assays and other fluid examinations. It is not possible to perform all these tests with a POCT methodology.
In another field, several rapid tests are used in ED to search for the drugs of abuse in urine. This represents a real analytical challenge as there are several categories of substances, sometimes with different metabolites and highly variable concentrations due to the different pharmacological potency. These simplified tests therefore have many limitations, present false positives and even more false negatives results. Furthermore, due to possible legal implications, they require subsequent confirmatory tests with definitive methods that are not suitable for clinical urgency. Because of these limited diagnostic performances, they should only be used in the case of elevated clinical suspicion of intoxication and not as a first screening test. There are no substantial data on the real clinical advantage offered using these tests in ED. 15 In respiratory disorders the value of blood gas analysis in ED is established and indisputable, as well as the value of electrolytes in case of fever or dyspnea for other causes. In newborn or very young patients, some studies have evaluated the use of C-reactive protein: it is a marker whose limitations are known, but in these cases a considerable advantage is offered by the use of capillary blood which is obtained more easily and does not contribute to the development of iatrogenic anemia. More recently, rapid molecular tests have been proposed for the diagnosis of influenza and other viruses. Now at least one of these methods seems to be reliable but there is no evidence of efficacy in reducing the use of antibiotics. 16 
Quality in point-of-care testing process
One of the main aspects concerning the adoption of POCT systems is quality assurance. There is in fact a native quality, that is the one guaranteed by the manufacturer, with a method that is valid from an analytical point of view and with an instrument that prevents errors in use. Table 1 shows how, on average, the analytical performance is not always comparable with that provided by the laboratories evidencing its insufficiency. It is also important that correct procedures for internal quality control are adopted with suitable materials and an external quality audit, while the pre-ana- lytical and post-analytical phases require integrating the POCT into the quality system of the whole ED. For this purpose, the specific International Organization for Standardization (ISO) 22870:2017 document for this activity must be followed for each clarification. 17 Rules and recommendations are provided for the training of personnel, their qualification to perform tests, maintenance procedures, technical validation of data and management of any panic values. The laboratory providing technical support must collaborate in all of this, interfacing the analyzers with the Laboratory Information System and ensuring the traceability of data.
Review

Errors and point-of-care testing
Laboratory errors occur mainly in the pre-analytical and postanalytic phases, as numerous publications have shown. 18, 19 This is expected from the numerous safety processes implemented in laboratories through analytical quality control systems. Contrarily in POCT, analytical errors prevail; 20 in fact, the pre-analytical phase is simplified, in particular when a primary container is not required with the biological fluid going directly to the analyzer. Conversely, the analytical phase is marked by two critical issues: the analytical method is limited because simplified to favor timeliness and the procedure is followed by nurses who have many other tasks. Table  2 shows the main types of errors that have been described in the POCT, divided into the different phases of the process. In the specific situation of the ED where there is a considerable crowd of users and frequent distractions to follow more urgent cases, the correct identification of the subject and the subsequent transcription of the results, however, remain at high risk of error. 21 Two are the interventions needed for avoiding or limiting the high risks related to an activity that often induce an immediate clinical decision: first, implementation of a quality system (as the ISO 22870:2017) for the whole process, with particular attention to the staff competency; second, activation of a reliable informatics connection between the patient identification, analyzer, Laboratory Information System, reports production and consultation.
Cost analysis
Financial impact with the use of POCT also needs to be evaluated to consider both the costs to the system and the cost to the patient. POCT per se was not found to reduce costs, despite reducing LOS and admissions. In fact, we can attribute the rising costs not only to the consumables, but also to the work time of the nurse, the training, the quality control, the computer interfacing and the commitment required by the laboratory staff. Among the ceasing costs we must include some consumables for blood samples, transport of tubes, time dedicated to the laboratory work, maintenance and the cost of reagents and analyzers. The evaluation of benefits is more difficult, as are the partial and uncertain conclusions of literature. For all these considerations it is not possible to express any judgment now. 22 
Conclusions
Clinical studies with a high value of evidence have investigated only some applications of POCT exams in ED, so we have no clear proof of the comparison between the tests performed at the Laboratory compared to decentralized tests.
POCT does not replace the clinical laboratory, but we must consider it as an extension of the laboratory that approaches the clinic and helps the ED staff in obtaining useful and safe reports in patient care. All this requires sharing and precise rules.
The need to accelerate the diagnostic process in ED is however very strong and requires continue experimenting with new technical solutions, albeit with the prudence required by the fragility of patients.
